Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials-Reference-Cited by-同舟云学术

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

Published:2023-03 Issue:3 Volume:7 Page:180-189
ISSN:2352-4642
Container-title:The Lancet Child & Adolescent Health
language:en
Short-container-title:The Lancet Child & Adolescent Health

Author:

Simões Eric A F,Madhi Shabir A,Muller William J,Atanasova Victoria,Bosheva Miroslava,Cabañas Fernando,Baca Cots Manuel,Domachowske Joseph B,Garcia-Garcia Maria L,Grantina Ineta,Nguyen Kim A,Zar Heather J,Berglind Anna,Cummings Celeste,Griffin M Pamela,Takas Therese,Yuan Yuan,Wählby Hamrén Ulrika,Leach Amanda,Villafana Tonya

Publisher

Elsevier BV

Subject

Developmental and Educational Psychology,Pediatrics, Perinatology and Child Health

Reference31 articles.

1. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study;Murray;PLoS One,2014

2. The burgeoning burden of respiratory syncytial virus among children;Hall;Infect Disord Drug Targets,2012

3. Respiratory syncytial virus-associated hospitalizations among young children: 2015–2016;Rha;Pediatrics,2020

4. Respiratory syncytial virus-associated acute lower respiratory infections in children with bronchopulmonary dysplasia: systematic review and meta-analysis;Chaw;J Infect Dis,2020

5. Acute lower respiratory infections associated with respiratory syncytial virus in children with underlying congenital heart disease: systematic review and meta-analysis;Chaw;J Infect Dis,2020

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY);Vaccine;2024-10

2. Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children;Pediatrics;2024-09-11

3. Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain;BMC Infectious Diseases;2024-09-06

4. An evaluation of 2015–2019 United States respiratory syncytial virus hospitalizations as a framework to develop potential strategies for the preventiosn of the hospital burden among infants;eClinicalMedicine;2024-09

5. Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case–control study;The Lancet Regional Health - Europe;2024-09